Channel
Yemaachi, Roche Launch African Cancer Atlas Initiative
The companies aim to establish a consortium and build a database of genomics and clinical information from 7,500 African cancer patients.
FDA Grants Priority Review to Chimerix for Dordaviprone in H3 K27M-Mutant Diffuse Glioma
In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.
Merck's Welireg Approved in Europe for Von Hippel-Lindau-Associated Cancers
The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.
FDA Grants Priority Review to Ultragenyx's BLA for Sanfilippo Syndrome Type A Gene Therapy
The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.
Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment
The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.